Microangiopathic hemolytic anemia (MAHA) is a type of anemia in which red blood cells are physically torn apart as they pass through damaged or obstructed small blood vessels. The destruction happens inside the bloodstream itself, not in the spleen or liver where old red blood cells are normally recycled. What makes MAHA distinctive is the cause of that destruction: tiny clots, abnormal vessel walls, or fibrin strands stretched across damaged blood vessels act like a cheese grater, shredding red blood cells into fragments called schistocytes.
MAHA is not a standalone disease. It’s a laboratory finding that points to an underlying condition, and identifying which condition is driving it determines the treatment.
How Red Blood Cells Get Destroyed
Under normal conditions, red blood cells are flexible discs that squeeze through the smallest capillaries without damage. In MAHA, something goes wrong with those small vessels. Tiny blood clots (microthrombi) form along vessel walls, or the vessel lining itself becomes damaged and irregular. As red blood cells are forced through these narrowed, obstructed passages under high pressure, they experience extreme shear stress and get sliced into fragments.
These fragments show up on a blood smear as schistocytes, recognizable by their distinctive shapes: triangles, crescents, and “helmet” forms. A schistocyte count above 1% of red blood cells is considered a confident threshold for diagnosing this type of damage, according to the International Council for Standardization in Haematology. The process also releases the contents of destroyed red blood cells into the bloodstream, triggering a cascade of measurable changes in blood tests.
How It’s Identified in Blood Work
Because red blood cells are being destroyed faster than the body can replace them, several lab markers shift in predictable ways. Haptoglobin, a protein that binds free hemoglobin released from broken red blood cells, drops as it gets used up. Lactate dehydrogenase (LDH), an enzyme released from damaged cells, rises. Unconjugated bilirubin, a waste product from hemoglobin breakdown, also increases, sometimes causing a yellowish tint to the skin or eyes.
At the same time, the bone marrow ramps up production of new red blood cells to compensate for the losses. This shows up as reticulocytosis, an elevated count of immature red blood cells in circulation. One important distinction: MAHA produces a negative direct antibody test (also called a Coombs test), meaning the immune system is not attacking the red blood cells. The damage is purely mechanical.
Conditions That Cause MAHA
The underlying conditions that trigger MAHA are collectively called thrombotic microangiopathies (TMAs), along with a few other disorders. Identifying which one is responsible is critical because treatments differ dramatically.
Thrombotic Thrombocytopenic Purpura (TTP)
TTP occurs when the body lacks a specific enzyme (ADAMTS13) that normally trims a large blood-clotting protein down to size. Without this enzyme, oversized clotting proteins accumulate and trigger widespread tiny clots throughout the body’s small blood vessels. Platelet counts drop sharply because platelets get consumed in forming these clots, and red blood cells are shredded as they pass through the obstructed vessels. The brain is particularly vulnerable, so neurological symptoms like confusion, headaches, and seizures are common warning signs.
The diagnostic hallmark is an ADAMTS13 activity level below 10%. This threshold was established because it captures nearly all patients who go on to experience relapses, making it a reliable cutoff. TTP can be acquired (the immune system attacks the enzyme) or inherited (a genetic deficiency). Without treatment, it is life-threatening, but plasma-based therapies that replace the missing enzyme have transformed outcomes.
Hemolytic Uremic Syndrome (HUS)
The most common form of HUS is triggered by infection with Shiga toxin-producing E. coli, typically after eating contaminated food or drinking contaminated water. Bloody diarrhea usually appears first, followed days later by kidney damage, low platelet counts, and MAHA. This form, called STEC-HUS, is confirmed by detecting Shiga toxin in stool samples. It’s most common in young children and often resolves with supportive care, though kidney function needs close monitoring.
Atypical HUS (aHUS) is a different beast. It stems from a malfunction in the complement system, the part of the immune system that helps clear infections and damaged cells. Genetic mutations affecting complement-regulating proteins are found in roughly one-third to one-half of patients. The kidneys bear the brunt of the damage. Unlike the infection-driven form, aHUS tends to recur and requires targeted treatment that blocks the overactive complement pathway.
Disseminated Intravascular Coagulation (DIC)
DIC is a dangerous condition where the body’s clotting system goes haywire, forming clots throughout small vessels while simultaneously depleting clotting factors and causing bleeding. It’s triggered by severe infections (sepsis), major trauma, certain cancers, and obstetric emergencies. DIC causes MAHA through the same mechanism of red blood cells shearing against microthrombi, but it has a distinct lab profile that separates it from TTP and HUS.
In DIC, clotting times (INR) are significantly prolonged and fibrinogen levels drop, because clotting factors are being consumed. D-dimer, a marker of clot breakdown, is very high. In TTP and most other TMAs, clotting times and fibrinogen stay relatively normal, and D-dimer is either normal or only mildly elevated. This distinction matters because the treatments are completely different.
HELLP Syndrome
HELLP syndrome is a pregnancy-related complication that combines hemolysis, elevated liver enzymes, and low platelets. It typically develops in the third trimester or shortly after delivery and represents a severe form of preeclampsia. The severity is graded by platelet count: the most severe form involves platelets below 50,000 per microliter with liver enzymes above 70 IU/L and LDH above 600 IU/L. Even the mildest form involves platelet counts between 100,000 and 150,000 per microliter with measurable liver enzyme elevation.
Delivery is the definitive treatment. Most patients recover within days to weeks after the pregnancy ends, though close monitoring for complications like liver rupture and kidney failure is essential during the acute phase.
Other Triggers
Not all MAHA is caused by clot-based microangiopathies. Mechanical heart valves and other cardiovascular devices can create enough turbulence to fragment red blood cells as they flow past artificial surfaces. Severe high blood pressure (malignant hypertension) damages small vessel walls directly, creating the same shearing effect. Certain cancers, particularly those that have spread widely, can trigger MAHA either through DIC or by tumor cells directly invading small blood vessels. Some medications, including certain chemotherapy drugs and immunosuppressants, can also damage the small vessel lining and cause MAHA.
What MAHA Feels Like
The symptoms of MAHA overlap with those of any significant anemia: fatigue, weakness, shortness of breath, pale skin, and a rapid heartbeat. Because the hemolysis releases hemoglobin into the bloodstream, urine may turn dark or tea-colored as the kidneys filter out the excess. Jaundice, a yellow discoloration of the skin and whites of the eyes, can develop from the buildup of bilirubin.
Beyond the anemia itself, symptoms vary depending on which organs the microthrombi are affecting. Kidney involvement produces decreased urine output and fluid retention. Brain involvement causes confusion, vision changes, or seizures. The combination of these organ-specific symptoms with anemia and easy bruising (from low platelets) is what typically prompts the blood work that reveals the diagnosis.
Because MAHA always signals an underlying process that needs urgent identification, the finding of schistocytes on a blood smear alongside low platelets and signs of hemolysis triggers a rapid diagnostic workup to distinguish between TTP, HUS, DIC, and other causes. The speed of that workup matters: TTP in particular carries a high mortality rate if treatment is delayed even by hours.